Clinical Trial

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Name: A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa — clinical trial record (NCT07287644)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: COMPASS 2-HS

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.

Protocol Amendment History 1 change

notable Trial sites expanded: 33 -> 58 locations 2026-05-30

Trial Details

NCT Number	NCT07287644
Lead Sponsor	Bluefin Biomedicine, Inc.
Conditions	Hidradenitis Suppurativa (HS)
Enrollment	210 participants
Start Date	2025-11-03
Primary Completion	2027-08-01 (estimated)
Study Completion	2027-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-29